Anita, multiple sclerosis, Norway

Built on patient insights and cutting-edge science and technology, Sanofi Genzyme is determined to help people living with neurological disorders by developing new treatment options and advancing patient care. 

With 18 years’ commitment in multiple sclerosis (MS), Sanofi Genzyme has relentlessly worked to improve the lives of the 2.3 million people worldwide living with this serious, life-long neuro-degenerative disease. Since the launch of its portfolio in 2012, Sanofi Genzyme has rapidly emerged as a leader in MS, bringing two therapies to patients in more than 80 countries worldwide. 

There is significant work left to be done, and Sanofi Genzyme is committed to accelerating the development of potential treatments for MS, amyotrophic lateral sclerosis, and other neurological diseases.

Inspired by patients worldwide
Dov, multiple sclerosis, Israel
Cassie, multiple sclerosis, Australia
Dave, multiple sclerosis, United Kingdom

Above from left to right: Dov, multiple sclerosis, Israel; Cassie, multiple sclerosis, Australia; Dave, multiple sclerosis, United Kingdom

Research & Development

Sanofi is pursuing best-in-class therapies for people living with neurological diseases, with its scientists deploying an array of technologies to develop new treatments that address the underlying cause of disease.

Related stories

How Multiple Sclerosis Affects the Brain

multiple sclerosis

Bringing New Hope to People Living with Multiple Sclerosis

Supporting Children whose Parents have Multiple Sclerosis